The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
New approaches to molecular cancer therapeutics
Open accessAbstract
Cancer drug development is leading the way in exploiting molecular biological and genetic information to develop 'personalized' medicine. The new paradigm is to develop agents that target the precise molecular pathology driving the progression of individual cancers. Drug developers have benefited from decades of academic cancer research and from investment in genomics, genetics and automation; their success is exemplified by high-profile drugs such as Herceptin (trastuzumab), Gleevec (imatinib), Tarceva (erlotinib) and Avastin (bevacizumab). However, only 5% of cancer drugs entering clinical trials reach marketing approval. Cancer remains a high unmet medical need, and many potential cancer targets remain undrugged. In this review we assess the status of the discovery and development of small-molecule cancer therapeutics. We show how chemical biology approaches offer techniques for interconnecting elements of the traditional linear progression from gene to drug, thereby providing a basis for increasing speed and success in cancer drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“Nevertheless, in vitro selectivity profiling using panels of isolated kinase”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Lessons from natural molecules
Clardy, J., & Walsh, C. (2004) · Nature · doi:10.1038/nature03194 · Cited by 1,171
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP
Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996) · Science · doi:10.1126/science.273.5272.239 · Cited by 929
Stem Cells and Cancer: Two Faces of Eve
Clarke, M. F., & Fuller, M. (2006) · Cell · doi:10.1016/j.cell.2006.03.011 · Cited by 905
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., & Austin, C. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604348103 · Cited by 792
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1970 · Cited by 789
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 1×
“Elucidation of human HDAC8 structures has shown that the surface adjacent to the conserved active site pocket is conformationally malleabl”
BackgroundPotent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Natural products in cancer chemotherapy: past, present and future
Mann, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc723 · Cited by 684
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Features of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Diversity-oriented synthesis: Exploring the intersections between chemistry and biology
Tan, D. S. (2005) · Nature Chemical Biology · doi:10.1038/nchembio0705-74 · Cited by 605
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Systems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.612 · Cited by 488
Self-citationWhitebread, S., Hamon, J., Bojanic, D., & Urban, L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03632-9 · Cited by 404
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Nonleadlikeness and leadlikeness in biochemical screening
Rishton, G. M. (2003) · Drug Discovery Today · doi:10.1016/s1359644602025722 · Cited by 381
Thomas, R. K., Nickerson, E., Simons, J. F., Jänne, P. A., Tengs, T., Yuza, Y., Garraway, L. A., LaFramboise, T., Lee, J. C., Shah, K., et al. (2006) · Nature Medicine · doi:10.1038/nm1437 · Cited by 361
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy
Putt, K. S., Chen, G. W., Pearson, J. M., Sandhorst, J. S., Hoagland, M. S., Kwon, J.-T., Hwang, S.-K., Jin, H., Churchwell, M. I., Cho, M.-H., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio814 · Cited by 354
Contributions of Human Tumor Xenografts to Anticancer Drug Development
Sausville, E. A., & Burger, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3627 · Cited by 348
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 329
The New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308
Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis
Nören-Müller, A., Reis-Corrêa, I., Prinz, H., Rosenbaum, C., Saxena, K., Schwalbe, H. J., Vestweber, D., Cagna, G., Schunk, S., Schwarz, O., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601490103 · Cited by 303
Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L., & Rosen, N. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00015-1 · Cited by 288
Kerns, E. H., Di, L., Petusky, S., Farris, M., Ley, R., & Jupp, P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20075 · Cited by 275
Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms
Wright, L., Barril, X., Dymock, B., Sheridan, L., Surgenor, A., Beswick, M., Drysdale, M., Collier, A., Massey, A., Davies, N., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.033 · Cited by 268
Self-citationGenetically Engineered Models Have Advantages over Xenografts for Preclinical Studies
Becher, O. J., & Holland, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3827 · Cited by 243
Brehmer, D., Greff, Z., Godl, K., Blencke, S., Kurtenbach, A., Weber, M., Müller, S., Klebl, B., Cotten, M., Kéri, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.379.65.2 · Cited by 241
Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling
Evans, M. J., Saghatelian, A., Sorensen, E. J., & Cravatt, B. F. (2005) · Nature Biotechnology · doi:10.1038/nbt1149 · Cited by 230
Dymock, B. W., Barril, X., Brough, P. A., Cansfield, J. E., Massey, A., McDonald, E., Hubbard, R. E., Surgenor, A., Roughley, S. D., Webb, P., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050355z · Cited by 227
Self-citationRatain, M. J., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.960 · Cited by 227
Cheung, K.-M. J., Matthews, T. P., James, K., Rowlands, M. G., Boxall, K. J., Sharp, S. Y., Maloney, A., Roe, S. M., Prodromou, C., Pearl, L. H., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.046 · Cited by 219
Self-citationCard, G. L., Blasdel, L., England, B. P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P. N., Artis, D. R., Bollag, G., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1059 · Cited by 208
Medicinal chemistry of target family-directed masterkeys
Müller, G. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02781-8 · Cited by 207
Nassar, A.-E. F., Kamel, A. M., & Clarimont, C. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03280-5 · Cited by 204
Cancer BiomarkersAn Invitation to the Table
Dalton, W. S., & Friend, S. H. (2006) · Science · doi:10.1126/science.1125948 · Cited by 202
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
Strumberg, D. (2005) · Drugs of Today · doi:10.1358/dot.2005.41.12.937959 · Cited by 195
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 189
Workman, P., Aboagye, E. O., Chung, Y.-L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P. M., & Zweit, J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj162 · Cited by 188
Self-citationIdentification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
Gill, A. L., Frederickson, M., Cleasby, A., Woodhead, S. J., Carr, M. G., Woodhead, A. J., Walker, M. T., Congreve, M. S., Devine, L. A., Tisi, D., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049575n · Cited by 186
Tools for kinetic modeling of biochemical networks
Alves, R., Antunes, F., & Salvador, A. (2006) · Nature Biotechnology · doi:10.1038/nbt0606-667 · Cited by 181
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
Sawyers, C. L. (2003) · Genes & Development · doi:10.1101/gad.1152403 · Cited by 170
Influence of Molecular Flexibility and Polar Surface Area Metrics on Oral Bioavailability in the Rat
Lu, J. J., Crimin, K., Goodwin, J. T., Crivori, P., Orrenius, C., Xing, L., Tandler, P. J., Vidmar, T. J., Amore, B. M., Wilson, A. G. E., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306529 · Cited by 169
Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I., & Workman, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0518 · Cited by 164
Self-citationValidating cancer drug targets
Benson, J. D., Chen, Y.-N. P., Cornell-Kennon, S. A., Dorsch, M., Kim, S., Leszczyniecka, M., Sellers, W. R., & Lengauer, C. (2006) · Nature · doi:10.1038/nature04873 · Cited by 161
Targeting protein–protein interactions for cancer therapy
Fry, D. C., & Vassilev, L. T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0705-x · Cited by 160
Applications of high-throughput ADME in drug discovery
Kassel, D. B. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.015 · Cited by 152
Workman, P. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455279 · Cited by 150
Self-citationDesign and Discovery of Small Molecules Targeting Raf-1 Kinase
Lowinger, T. B., Riedl, B., Dumas, J., & Smith, R. A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 150
Barnett, S., Bilodeau, M. T., & Lindsley, C. W. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507714 · Cited by 146
Synthesis and Target Identification of Hymenialdisine Analogs
Wan, Y., Hur, W., Cho, C. Y., Liu, Y., Adrian, F. J., Lozach, O., Bach, S., Mayer, T., Fabbro, D., Meijer, L., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.01.015 · Cited by 140
A Three-Hybrid Approach to Scanning the Proteome for Targets of Small Molecule Kinase Inhibitors
Becker, F., Murthi, K. K., Smith, C. C., Come, J. H., COSTAROLDAN, N., Kaufmann, C. M., Hanke, U., Degenhart, C., Baumann, S. W., Wallner, W., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.001 · Cited by 139
Finding the target after screening the phenotype
Hart, C. P. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03415-x · Cited by 131
Hexachlorophene Inhibits Wnt/β-Catenin Pathway by Promoting Siah-Mediated β-Catenin Degradation
Park, S., Gwak, J., Cho, M., Song, T., Won, J., Kim, D., Shin, J., & Oh, S. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024729 · Cited by 118
Blencke, S., Ullrich, A., & Daub, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211158200 · Cited by 117
A Genome-Wide Overexpression Screen in Yeast for Small-Molecule Target Identification
Luesch, H., Wu, T. Y.-H., Ren, P., Gray, N. S., Schultz, P. G., & Supek, F. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.015 · Cited by 114
Lyne, P. D., Kenny, P. W., Cosgrove, D. A., Deng, C., Zabludoff, S., Wendoloski, J. J., & Ashwell, S. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030504i · Cited by 113
Components of Successful Lead Generation
Davis, A., Keeling, D., Steele, J., Tomkinson, N. P., & Tinker, A. C. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053828411 · Cited by 110
Workman, P. (2003) · PubMed · Cited by 105
Self-citationComplex phenotypic assays in high-throughput screening
Clemons, P. A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.002 · Cited by 102
Chemical Genetic Modifier Screens
Koeller, K. M., Haggarty, S. J., Perkins, B. D., Leykin, I., Wong, J. C., Kao, M.-C. J., & Schreiber, S. L. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00093-0 · Cited by 89
The Discovery of NVP-LAQ824: From Concept to Clinic
Remiszewski, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456675 · Cited by 88
Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases
Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.030 · Cited by 80
Workman, P., Clarke, P. A., Guillard, S., & Raynaud, F. I. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-794 · Cited by 78
Self-citationInhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
McDonald, E., Workman, P., & Jones, K. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812004 · Cited by 75
Self-citationDw, F. (2000) · PubMed · Cited by 72
Identification of Potent Ras Signaling Inhibitors by Pathway‐Selective Phenotype‐Based Screening
Müller, O., Gourzoulidou, E., Carpintero, M., Karaguni, I., Langerak, A., Herrmann, C., Möröy, T., Klein‐Hitpaß, L., & Waldmann, H. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200352587 · Cited by 71
Challenges of PK/PD measurements in modern drug development
Workman, P. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00395-7 · Cited by 65
Self-citationThe Purinome, a Complex Mix of Drug and Toxicity Targets
Haystead, T. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812059 · Cited by 58
Morgan-Lappe, S. E., Woods, K. W., Li, Q., Anderson, M. G., Schurdak, M. E., Luo, Y., Giranda, V. L., Fesik, S. W., & Leverson, J. D. (2005) · Oncogene · doi:10.1038/sj.onc.1209169 · Cited by 53
Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA
Obata, K., Sugano, K., Machida, M., & Aso, Y. (2004) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120028713 · Cited by 53
Genomics and the second golden era of cancer drug development
Workman, P. (2005) · Molecular BioSystems · doi:10.1039/b501751n · Cited by 53
Self-citationTelomerase as a Target for Cancer Immunotherapy
Nguyen, B., Elmore, L. W., & Holt, S. E. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.2.255 · Cited by 48
Marsham, P. R., Wardleworth, J. M., Boyle, F. T., Hennequin, L. F., Kimbell, R., Brown, M., & Jackman, A. L. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9803727 · Cited by 46
Raynaud, F. I., Fischer, P. M., Nutley, B. P., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.353.3.3 · Cited by 44
Workman, P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.020 · Cited by 40
Self-citationSelective Kinase Inhibition by Exploiting Differential Pathway Sensitivity
Kung, C. K.-H., Kenski, D. M., Krukenberg, K. A., Madhani, H. D., & Shokat, K. M. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.02.004 · Cited by 31
Wolff, M., Haasen, D., Merk, S., Kroner, M., Maier, U., Bordel, S., Wiedenmann, J., Nienhaus, G. U., Valler, M. J., & Heilker, R. (2006) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620706777452447 · Cited by 27
Chatterjee‐Kishore, M., & Miller, C. P. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03623-8 · Cited by 24
Newbatt, Y. M., Burns, S., Hayward, R., Whittaker, S. R., Kirk, R., Marshall, C. J., Springer, C. J., McDonald, E., Cancer Genome Project, Marais, R., et al. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105283584 · Cited by 20
Self-citationCompound Selection and Filtering in Library Design
Lumley, J. A. (2005) · QSAR & Combinatorial Science · doi:10.1002/qsar.200520136 · Cited by 18
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Guidelines for the welfare and use of animals in cancer research
An ad hoc committee of the National Cancer Research Institute, Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,442
Self-citationDrug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
Metadata
- Authors
- Collins, I., & Workman, P.
- Venue
- Nature Chemical Biology
- Published
- 2006-12
- Volume
- 2
- Issue
- 12
- Pages
- 689-700
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2012047645
- Cited by
- 391
- References
- 122
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.